Related references
Note: Only part of the references are listed.Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Silvia Pascale et al.
BLOOD (2012)
Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome
James P. Smith et al.
HYPERTENSION (2012)
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia
Sarah J. Barsam et al.
BLOOD (2011)
Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease
Davide Capodanno et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2011)
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
Marie Lordkipanidze et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease
Patrick Henry et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications
Galia Spectre et al.
THROMBOSIS AND HAEMOSTASIS (2011)
The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy
Alfredo Dragani et al.
BLOOD (2010)
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation
Michael Pignone et al.
CIRCULATION (2010)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Michael J. Hanley et al.
CLINICAL PHARMACOKINETICS (2010)
Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes
Faouzi Addad et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization
Andrew L. Frelinger et al.
CIRCULATION (2009)
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment
Fabio M. Pulcinelli et al.
EUROPEAN HEART JOURNAL (2009)
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays Implications for Aspirin Resistance
Francesca Santilli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Giorgia De Berardis et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes A Randomized Controlled Trial
Hisao Ogawa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
Jill Belch et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients - An analysis from the aspirin-induced platelet effect (ASPECT) study
Joseph DiChiara et al.
DIABETES (2007)
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin
V. Evangelista et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Platelet PMCA- and SERCA-type Ca2+-ATPase expression in diabetes:: a novel signature of abnormal megakaryocytopoiesis
C. Chaabane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT- D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
Giorgia De Berardis et al.
TRIALS (2007)
Drug therapy -: Low-dose aspirin for the prevention of atherothrombosis
C Patrono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease
AO Maree et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Determinants of the interindividual variability in response to antiplatelet drugs
B Rocca et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Share Paper
